<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04284436</url>
  </required_header>
  <id_info>
    <org_study_id>1U01NS113851-01</org_study_id>
    <nct_id>NCT04284436</nct_id>
  </id_info>
  <brief_title>Study in Parkinson Disease of Exercise</brief_title>
  <acronym>SPARX3</acronym>
  <official_title>Study in Parkinson Disease of Exercise Phase 3 Clinical Trial: SPARX3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Parkinson Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance&#xD;
      treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease&#xD;
      Rating Scale (MDS-UPDRS) Part III score at 12 months among persons with early stage Parkinson&#xD;
      disease. 370 participants will be randomly assigned to 2 groups: 1)60-65% HRmax or 2)80-85%&#xD;
      HRmax 4 times per week. The primary objective is to test whether the progression of the signs&#xD;
      of Parkinson's disease is attenuated at 12 months in among persons who have not initiated&#xD;
      medication for Parkinson Disease (PD) when they perform high-intensity endurance treadmill&#xD;
      exercise.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance&#xD;
      treadmill exercise on changes in the MDS-UPDRS Part III score at 12 months. 370 persons&#xD;
      diagnosed with Parkinson's disease who have not yet initiated dopaminergic therapy, age&#xD;
      40-80, will be randomly assigned to 2 groups: 1)60-65% HRmax or 2)80-85% HRmax 4 times per&#xD;
      week. Secondary objectives will test hypotheses related to striatal specific binding ratio&#xD;
      (SSBR) at 12 months, MDS-UPDRS Part III score, ambulatory mobility (6-minute walk), daily&#xD;
      walking activity (steps), cognition, quality of life, cardiorespiratory fitness,&#xD;
      blood-derived biomarkers of inflammation and neurotrophic factors at 12 and 18 months.&#xD;
      Tertiary objectives will test hypotheses related to 2 characteristics of ambulation at 12 and&#xD;
      18 months. Exploratory objectives will test hypotheses related to the effects of removing the&#xD;
      study support that was provided over 18 months on the sustainability and durability of the&#xD;
      exercise effects at 24 months. Approximately 29 sites will enroll participants: 27 sites that&#xD;
      cover all geographic regions of the USA and 2 sites in Canada. All sites will have a&#xD;
      collaboration between movement disorders and exercise specialists.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in motor symptoms of Parkinson disease</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in the Movement Disorders Society-Unified Parkinson Disease Rating Scale motor score (Part III). The minimum score on the MDS-UPDRS Part III is 0 and the maximum is 132 with higher scores representing worse motor symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in dopaminergic activity</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in the striatal specific binding ratio (SSBR) as measured by dopamine transporter imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in motor symptoms of Parkinson disease</measure>
    <time_frame>18 months</time_frame>
    <description>Change from baseline in the Movement Disorders Society-Unified Parkinson Disease Rating Scale motor score (Part III). The minimum score on the MDS-UPDRS Part III is 0 and the maximum is 132 with higher scores representing worse motor symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in walking capacity</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in distance in 6-minute walk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in walking capacity</measure>
    <time_frame>18 months</time_frame>
    <description>Change from baseline in distance in 6-minute walk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in activity</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in the number of steps</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in activity</measure>
    <time_frame>18 months</time_frame>
    <description>Change from baseline in the number of steps</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive function</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in the Montreal Cognitive Assessment (MoCA). MoCA scores range between 0 and 30, with higher scores representing a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive function</measure>
    <time_frame>18 months</time_frame>
    <description>Change from baseline in the Montreal Cognitive Assessment (MoCA). MoCA scores range between 0 and 30, with higher scores representing a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fitness</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in maximal oxygen consumption measured with peak oxygen volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fitness</measure>
    <time_frame>18 months</time_frame>
    <description>Change from baseline in maximal oxygen consumption measured with peak oxygen volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in quality of life measured with the Parkinson Disease Questionnaire-39. The PDQ-39 is a 39-item self-report questionnaire, which assesses Parkinson's disease-specific health related quality over the last month covering 8 dimensions scored on a 5 point ordinal system (0=never, 4=always). Dimension score = sum of scores of each item in the dimension divided by the maximum possible score of all the items in the dimension, multiplied by 100. Each dimension total score range from 0 (never have difficulty) to 100 (always have difficulty). Lower scores reflect better QoL. Overall score can be summarized in the Parkinson's Disease Summary Index (PDSI) or PDQ-39 Summary Index (PDQ-39 SI).PDSI or PDQ-39 SI = sum of dimension total scores divided by 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>18 months</time_frame>
    <description>Change from baseline in quality of life measured with the Parkinson Disease Questionnaire-39. The PDQ-39 is a 39-item self-report questionnaire, which assesses Parkinson's disease-specific health related quality over the last month covering 8 dimensions scored on a 5 point ordinal system (0=never, 4=always). Dimension score = sum of scores of each item in the dimension divided by the maximum possible score of all the items in the dimension, multiplied by 100. Each dimension total score range from 0 (never have difficulty) to 100 (always have difficulty). Lower scores reflect better QoL. Overall score can be summarized in the Parkinson's Disease Summary Index (PDSI) or PDQ-39 Summary Index (PDQ-39 SI).PDSI or PDQ-39 SI = sum of dimension total scores divided by 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initiation of dopaminergic therapy</measure>
    <time_frame>12 months</time_frame>
    <description>Time to initiation of dopaminergic therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood derived marker of inflammation</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in C-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood derived marker of inflammation</measure>
    <time_frame>18 months</time_frame>
    <description>Change from baseline in C-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood derived marker of neuronal development</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in brain derived neurotrophic factor (BDNF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood derived marker of neuronal development</measure>
    <time_frame>18 months</time_frame>
    <description>Change from baseline in brain derived neurotrophic factor (BDNF)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in stride length</measure>
    <time_frame>12 months</time_frame>
    <description>Change in stride length assessed using OPAL movement monitors during the 6 minute walk test</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in stride length</measure>
    <time_frame>18 months</time_frame>
    <description>Change in stride length assessed using OPAL movement monitors during the 6 minute walk test</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in turning velocity</measure>
    <time_frame>12 months</time_frame>
    <description>Change in turning velocity assessed using OPAL movement monitors during the 6 minute walk test</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in turning velocity</measure>
    <time_frame>18 months</time_frame>
    <description>Change in turning velocity assessed using OPAL movement monitors during the 6 minute walk test</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">370</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>High Intensity Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treadmill exercise 4x per week at 80-85% HRmax.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Intensity Exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treadmill exercise 4x per week at 60-65% HRmax.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Treadmill walking</intervention_name>
    <description>Treadmill walking 4 days per week for 30 minutes in the target heart rate</description>
    <arm_group_label>High Intensity Exercise</arm_group_label>
    <arm_group_label>Moderate Intensity Exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A diagnosis of idiopathic Parkinson Disease based on the modified * United Kingdom&#xD;
             (UK) PD brain bank criteria and which are consistent with recent criteria proposed for&#xD;
             clinically established early established Parkinson's disease that no longer exclude&#xD;
             individuals with a family history of Parkinson's disease.&#xD;
&#xD;
          -  Hoehn and Yahr stages less than 3&#xD;
&#xD;
          -  Disease duration: less than 3 years since disease diagnosis&#xD;
&#xD;
          -  Age 40-80 years&#xD;
&#xD;
          -  Positive DaTscan™ SPECT by quantitative readout for idiopathic Parkinson disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently being treated with PD medications such as levodopa or dopamine receptor&#xD;
             agonists, monoamine oxidase-B (MAO-B) inhibitors, amantadine, or anticholinergics.&#xD;
&#xD;
          -  Expected to require treatment with medication for PD in the first 6 months of the&#xD;
             study.&#xD;
&#xD;
          -  Use of any PD medication 60 days prior to the baseline visit including but not limited&#xD;
             to levodopa, direct dopamine agonists, amantadine, Rasagiline (Azilect), Selegiline&#xD;
             (Eldepryl), Artane (trihexyphenidyl).&#xD;
&#xD;
          -  Duration of previous use of medications for PD exceeds 60 days.&#xD;
&#xD;
          -  Use of neuroleptics/dopamine receptor blockers for more than 30 days in the year prior&#xD;
             to baseline visit, or any use within 30 days of baseline visit&#xD;
&#xD;
          -  Presence of known cardiovascular, metabolic, or renal disease or individuals with&#xD;
             major signs or symptoms suggestive of cardiovascular, metabolic, or renal disease&#xD;
             without medical clearance to participate in the exercise program.&#xD;
&#xD;
          -  Uncontrolled hypertension (resting blood pressure &gt;150/90 mmHg)&#xD;
&#xD;
          -  Individuals with orthostatic hypotension and standing systolic BP below 100 will be&#xD;
             excluded. Orthostatic hypotension (OH) is a reduction of systolic blood pressure of at&#xD;
             least 20 mm Hg or diastolic blood pressure of at least 10 mm Hg within 3 minutes of&#xD;
             standing.&#xD;
&#xD;
          -  Hypo- or hyperthyroidism (TSH &lt;0.5 or &gt;5.0 mU/L), abnormal liver function (AST or ALT&#xD;
             more than 2 times the upper limit of normal), abnormal renal function (creatinine&#xD;
             clearance calculated by the Cockcroft-Gault equation &lt;50mL/min, or estimated&#xD;
             glomerular filtration rate using the MDRD4 equation or the CKD-EPI equation&#xD;
             &lt;45mL/min/1.73m2 ).&#xD;
&#xD;
          -  Complete Blood Count (CBC) out of range and physician's judgment that abnormal value&#xD;
             is clinically significant.&#xD;
&#xD;
          -  Recent use of psychotropic medications (e.g., anxiolytics, hypnotics, benzodiazepines,&#xD;
             antidepressants) where dosage has not been stable for 28 days prior to screening.&#xD;
&#xD;
          -  Serious illness (requiring systemic treatment and/or hospitalization) within the last&#xD;
             4 weeks.&#xD;
&#xD;
          -  Any other clinically significant medical condition, psychiatric condition, drug or&#xD;
             alcohol abuse, assessment or laboratory abnormality that would, in the judgment of the&#xD;
             investigator, interfere with the subject's ability to participate in the study.&#xD;
&#xD;
          -  Montreal Cognitive Assessment (MoCA) score of &lt;24.&#xD;
&#xD;
          -  Beck Depression Inventory II (BDI) score &gt; 28, indicating severe depression that&#xD;
             precludes ability to exercise. Any subject with such a score will be referred to a PCP&#xD;
             or physician for further evaluation and management of depression. Individuals with a&#xD;
             BDI-II score of 17-28 will be excluded if any of the following conditions are met: (1)&#xD;
             individual is suicidal, (2) is in need of depression treatment modification currently&#xD;
             or (3) depressive symptoms likely to interfere with adherence to study protocol. Any&#xD;
             subject with such a score will be referred to a PCP or physician for further&#xD;
             evaluation and management of depression.&#xD;
&#xD;
          -  Individuals who have been exercising at greater than moderate intensity for 120&#xD;
             minutes or more per week consistently over the last 6 months will be excluded. Greater&#xD;
             than moderate intensity is defined as a range greater than 60-65% HRmax. These&#xD;
             individuals are excluded since their exercise activities are greater than the&#xD;
             activities they would experience if they were assigned to the 60-65% treatment group.&#xD;
             As such, they would be expected to lose fitness.&#xD;
&#xD;
          -  Use of the following within 90 days prior to the dopamine transporter (DAT)&#xD;
             neuroimaging screening evaluation: bupropion, modafinil, armodafinil, metoclopramide,&#xD;
             alpha-methyldopa, methylphenidate, reserpine, any amphetamine or amphetamine&#xD;
             derivative. These can compromise DaTscan™ SPECT.&#xD;
&#xD;
          -  Known allergy to iodinated products.&#xD;
&#xD;
          -  Known hypersensitivity to DaTscan™ SPECT (either to the active substance of&#xD;
             123I-ioflupane or any of the excipients.&#xD;
&#xD;
          -  (For women only) Actively breast-feeding an infant, and/or pregnant, or plan to become&#xD;
             pregnant in the next 12 months.&#xD;
&#xD;
          -  Other disorders, injuries, diseases, or conditions that might interfere with ability&#xD;
             to perform endurance exercises (e.g. history of stroke, respiratory problems,&#xD;
             traumatic brain injury, orthopedic injury, or neuromuscular disease).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel M Corcos, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Joslin</last_name>
    <phone>309-922-7254</phone>
    <email>elizabeth.joslin@northwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ariel Kidwell</last_name>
      <email>b010@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Motl, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinna Conroy</last_name>
      <phone>415-502-2960</phone>
      <email>corinna.conroy@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Carlie Tanner</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nijee Luthra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado, Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Balfany</last_name>
      <phone>303-724-9101</phone>
      <email>SPARX3@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Cory Christiansen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Fessenden</last_name>
      <phone>352-733-2421</phone>
      <email>amanda.fessenden@neurology.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Demetra Christou, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morehouse School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30310</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paula Phabian-Millbrook</last_name>
      <phone>404-756-5053</phone>
      <email>parkinsonstudy@msm.edu</email>
    </contact>
    <investigator>
      <last_name>Chantale Branson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joe Nocera, PhD</last_name>
      <phone>404-321-6111</phone>
      <phone_ext>206354</phone_ext>
      <email>joenocera@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Joe Nocera, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Garett Griffith</last_name>
      <phone>708-703-2591</phone>
      <email>garett.griffith@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Cynthia Poon, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Solonowicz</last_name>
      <phone>312-563-5564</phone>
      <email>Olga_Solonowicz@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Mitra Afshari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Iowa State University</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Stegemoller, PhD</last_name>
      <phone>515-294-5966</phone>
      <email>esteg@iastate.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Stegemoller, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisiana State University</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Hondzinski, PhD</last_name>
      <phone>225-578-9144</phone>
      <email>jhondz1@lsu.edu</email>
    </contact>
    <investigator>
      <last_name>Jan Hondzinski, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston University (Charles River Campus)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Stevenson</last_name>
      <phone>617-638-7747</phone>
      <email>msteven1@bu.edu</email>
    </contact>
    <investigator>
      <last_name>Terry Ellis, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacob Haus, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jacob Haus, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Colum MacKinnon, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anhar Hassan, MB, BCh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martha Hessler</last_name>
      <phone>314-286-1478</phone>
      <email>mjhessler@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Gammon Earhart, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caitlin Romano</last_name>
      <phone>646-501-4367</phone>
      <email>caitlin.romano@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Patrick Drummond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corey Landis</last_name>
      <phone>212-305-1647</phone>
      <email>cl4129@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Ashwini Rao, EdD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessica Marchbank</last_name>
      <phone>513-558-4811</phone>
      <email>jessica.doak@uc.edu</email>
    </contact>
    <investigator>
      <last_name>Alberto Espay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MacKenzie Dunlap</last_name>
      <phone>216-444-7474</phone>
      <email>sparx@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Jay Alberts, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio Health</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kitra Hunter</last_name>
      <phone>614-566-1262</phone>
      <email>kitra.hunter@ohiohealth.com</email>
    </contact>
    <investigator>
      <last_name>David Hinkle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kent State University</name>
      <address>
        <city>Kent</city>
        <state>Ohio</state>
        <zip>44240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisar Khawam</last_name>
      <phone>216-844-1800</phone>
      <email>elisar.khawam@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Angela Ridgel, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graham Harker</last_name>
      <phone>503-418-2601</phone>
      <email>harkerg@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Martina Mancini, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcela Pavon</last_name>
      <phone>215-829-7725</phone>
      <email>Marcela.Pavon@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Whitney Hartstone</last_name>
      <phone>215-829-7725</phone>
      <email>whitney.hartstone@pennmedicine.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Andres Diek Acost Madiedo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Betts</last_name>
      <phone>412-443-8079</phone>
      <email>kmb251@pitt.edu</email>
    </contact>
    <investigator>
      <last_name>Deborah Josbeno, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Brand</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Summer Chapman</last_name>
      <phone>409-266-9666</phone>
      <email>srchapma@utmb.edu</email>
    </contact>
    <investigator>
      <last_name>Blake Rasmussen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genevieve &quot;G&quot; Olivier</last_name>
      <phone>801-587-3181</phone>
      <email>g.olivier@utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Erin Suttman</last_name>
      <phone>801-587-3181</phone>
      <email>erin.suttman@utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lee Dibble, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Art Weltman, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Krista Nelles</last_name>
      <phone>780-248-2043</phone>
    </contact>
    <investigator>
      <last_name>Richard Camicioli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wildred Laurier University of Canada</name>
      <address>
        <city>Waterloo</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Quincy Almeida, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schenkman M, Moore CG, Kohrt WM, Hall DA, Delitto A, Comella CL, Josbeno DA, Christiansen CL, Berman BD, Kluger BM, Melanson EL, Jain S, Robichaud JA, Poon C, Corcos DM. Effect of High-Intensity Treadmill Exercise on Motor Symptoms in Patients With De Novo Parkinson Disease: A Phase 2 Randomized Clinical Trial. JAMA Neurol. 2018 Feb 1;75(2):219-226. doi: 10.1001/jamaneurol.2017.3517.</citation>
    <PMID>29228079</PMID>
  </reference>
  <reference>
    <citation>Moore CG, Schenkman M, Kohrt WM, Delitto A, Hall DA, Corcos D. Study in Parkinson disease of exercise (SPARX): translating high-intensity exercise from animals to humans. Contemp Clin Trials. 2013 Sep;36(1):90-8. doi: 10.1016/j.cct.2013.06.002. Epub 2013 Jun 14.</citation>
    <PMID>23770108</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Daniel Corcos</investigator_full_name>
    <investigator_title>Professor of Physical Therapy and Human Movement Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All study data (deidentified) and documentation will be shared with the National Institute of Neurological Disease and Stroke.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>18 months after the study end.</ipd_time_frame>
    <ipd_access_criteria>Once the data are in the NINDS data repository, NINDS will be responsible for determining with whom the data are shared. No data will be shared directly from the study data coordinating center.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 16, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT04284436/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

